Diane M. Del Valle

Mount Sinai Hospital — United States

Medicine · Health Sciences

24h-index8.2kcitations122works0.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(41), Colorectal Cancer Treatments and Studies(29), HER2/EGFR in Cancer Research(27), COVID-19 Clinical Research Studies(23), Cancer Immunotherapy and Biomarkers(21)

Publications120 total

513 Advanced analytics identify a differential immune response to CAN-2409+valacyclovir in non-squamous vs squamous NSCLC, linked to improved survival in patients with progressive ICI-refractory NSCLC
Regular and Young Investigator Award Abstracts·2025Open Access
P2.08.23 Safety and Biomarker Analysis of Nrg-Lu004: Phase I Trial of Radiotherapy With Durvalumab in PD-L1 High LA-NSCLC
Journal of Thoracic Oncology·2025
T cell epitope mapping reveals immunodominance of evolutionarily conserved regions within SARS-CoV-2 proteome
iScience·2025· 1 citedOpen Access
Supplementary Table 2 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma
2025Open Access
Supplementary Table 3 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma
2025Open Access
Figure S2 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma
2025Open Access
Figure S1 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma
2025Open Access
Supplementary Table 1 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma
2025Open Access
Figure S3 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma
2025Open Access
A multi-institutional phase 1 clinical trial exploring upfront multimodal standard of care and combined immunotherapies for newly diagnosed glioblastoma
Neuro-Oncology·2025· 4 citedOpen Access
Peripheral Transcriptomics in Acute and Long-Term Kidney Dysfunction in SARS-CoV-2 Infection
Kidney360·2025· 6 citedOpen Access
Immunological biomarkers of response and resistance to treatment with cabozantinib and nivolumab in recurrent endometrial cancer
Journal for ImmunoTherapy of Cancer·2025· 7 citedOpen Access
Baseline colitogenicity and acute perturbations of gut microbiota in immunotherapy-related colitis
The Journal of Experimental Medicine·2024· 5 citedOpen Access
621 Interim analysis of a phase II study of talimogene laherparepvec (T-VEC) followed by combination T-VEC + nivolumab in non-melanoma skin cancers and refractory cutaneous lymphoma (NCI#10057)
Regular and Young Investigator Award Abstracts·2024Open Access
T cell epitope mapping reveals immunodominance of evolutionarily conserved regions within SARS-CoV-2 proteome.
2024· 2 citedOpen Access
Data from Immune Profiling Mass Cytometry Assay Harmonization: Multicenter Experience from CIMAC-CIDC
2024Open Access
Supplementary Materials and Methods from Multiplex Tissue Imaging Harmonization: A Multicenter Experience from CIMAC-CIDC Immuno-Oncology Biomarkers Network
2024Open Access
Figure S2 from Multiplex Tissue Imaging Harmonization: A Multicenter Experience from CIMAC-CIDC Immuno-Oncology Biomarkers Network
2024Open Access
Data from Multiplex Tissue Imaging Harmonization: A Multicenter Experience from CIMAC-CIDC Immuno-Oncology Biomarkers Network
2024Open Access
Supplementary Tables from Multiplex Tissue Imaging Harmonization: A Multicenter Experience from CIMAC-CIDC Immuno-Oncology Biomarkers Network
2024Open Access
page 1 of 6Next →

Frequent Co-authors

Sacha Gnjatic(39), Alexander W. Charney(27), Seunghee Kim‐Schulze(25), Miriam Mérad(23), Nicole W. Simons(19), Noam D. Beckmann(17), Kevin Tuballes(17), Edgar Gonzalez‐Kozlova(17), Hui Xie(16), Manishkumar Patel(16), Konstantinos Mouskas(16), Adeeb Rahman(15), Ryan C. Thompson(15), Eric E. Schadt(14), Gabriel E. Hoffman(13), Esther Cheng(13), Nancy Francoeur(12), Kimberly Argueta(12), Daniel Geanon(11), Kai Nie(11)